| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tacrolimus | CTRPv2 | pan-cancer | AAC | -0.024 | 0.5 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | 0.021 | 0.5 |
| mRNA | GDC-0449 | GDSC1000 | pan-cancer | AAC | 0.023 | 0.5 |
| mRNA | QS11 | GDSC1000 | pan-cancer | AAC | 0.023 | 0.5 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | -0.03 | 0.5 |
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | 0.021 | 0.5 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.022 | 0.5 |
| mRNA | SB 505124 | GDSC1000 | pan-cancer | AAC | -0.022 | 0.5 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | -0.049 | 0.5 |
| mRNA | BRD-K34099515 | CTRPv2 | pan-cancer | AAC | -0.05 | 0.5 |